RxDoctor Payments Data

Jose Acosta, PA

Medical · San Antonio, TXNPI 1720085434

Payments from drug & device makers

$4,424in general payments, 2019–2025

Across 214 payments — averaging $20.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$918
  • Boehringer Ingelheim$646
  • Lilly USA, LLC$605
  • Sanofi-aventis U.S. LLC$282
  • Bayer$246
  • Johnson & Johnson$242
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$4,424100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,424 in reported general payments places this provider in the 80th percentile of 1,490 medical providers in Texas.

See all medical providers in Texas

Medicare billing

Part B allowed, 2024
$15,817
Medicare patients
97
Services billed
272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin116$178,393
JanuviaSitagliptin Phosphate41$57,105
OzempicSemaglutide45$51,899
TrulicityDulaglutide32$47,841
EliquisApixaban43$39,616
LinzessLinaclotide27$26,548
MyrbetriqMirabegron24$20,387
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$18,868
MounjaroTirzepatide14$18,310
JanumetSitagliptin Phos/Metformin Hcl19$15,147
Tresiba Flextouch U-100Insulin Degludec19$12,565
Janumet XrSitagliptin Phos/Metformin Hcl16$11,085
BrilintaTicagrelor12$5,419
Rosuvastatin Calcium216$3,285
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$646$178,393116 claims
MerckJanuvia, Janumet, Janumet Xr$144$83,33776 claims
Lilly USA, LLCTrulicity, Mounjaro$605$66,15146 claims
Novo NordiskOzempic$918$51,89945 claims
PfizerEliquis$70$39,61643 claims
AbbVieLinzess$74$26,54827 claims
Astellas Pharma US IncMyrbetriq$18$20,38724 claims
AstraZenecaBrilinta$55$5,41912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,490 medical providers in Texas.

Other medical in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →